ALK inhibitors, resistance development, clinical trials

• Published in: Current oncology (Toronto) Vol. 25; no. Suppl 1; pp. S59 - 67
• Main Authors: Rothenstein, J M, Chooback, N
• Format: Journal Article
• Language: English
• Published: Switzerland Multimed Inc 01-06-2018
• Subjects: Anaplastic Lymphoma Kinase - antagonists & inhibitors; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Clinical Trials as Topic - methods; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - genetics; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Molecular Targeted Therapy; Precision Medicine; Protein Kinase Inhibitors - therapeutic use; Research Design; Review; brigatinib; cns metastases; crizotinib; alk inhibitors; nsclc; ceritinib; resistance; alectinib
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3747/co.25.3760

The treatment of advanced non-small-cell lung cancer (nsclc) has undergone a paradigm shift since the early 2000s. The identification of molecular subtypes of the disease, based on oncogenic drivers, has led to the development of personalized medicine and the ability to deliver molecularly targeted therapies to patients. In the 10 years that have elapsed since the discovery of the
gene in a patient with nsclc, several active drugs have moved rapidly from bench to bedside, and multiple others are currently in clinical trials. Those developments have led to important improvements in patient outcomes, while simultaneously raising key questions about the optimal treatment for
-positive nsclc. The inevitable emergence of resistance to alk-directed therapy is central to ongoing research and daily clinical practice for affected patients. In the present review, we highlight the current treatment landscape, the available and emerging clinical trials, and the evolving clinical decision-making in
-positive nsclc, with a focus on Canadian practice.